EXPD vs RPRX · P/E 26, rev $6.29B vs P/E 15, rev $1.30B
Expeditors International of Washington, Inc. (EXPD) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
Expeditors International of Washington, Inc. (EXPD) is a integrated freight & logistics company listed on NYSE.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported EXPD revenue for 2026-06-30 was $6.29B. Net income was $495.8M. EXPD currently screens at market cap $21.01B and trailing P/E 26.0.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
EXPD currently screens at market cap $21.01B and trailing P/E 26.0. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the EXPD and RPRX stock pages for the full models.
Not investment advice.